Program Type
Disease
Project Status

Displaying 1 - 17 of 17

AMP Amyotrophic Lateral Sclerosis
The Accelerating Medicines Partnership® (AMP®) Amyotrophic Lateral Sclerosis (AMP ALS) is accelerating therapeutic and biomarker developme...
The Pew Scholars and Fellows Program in the Biomedical Sciences
Overview The Pew Biomedical Scholars Program provides funding to young investigators of outstanding promise in science relevant to the adva...
The Biomedical Research Community Responds to the Opioids Crisis
Overview Opioid addiction, misuse and overdose is an ongoing and rapidly evolving public health crisis. According to the Centers for Diseas...
Sayer Vision Research Lecture & Award
Overview In 2006, Dr. Jane Sayer, an NIH Research scientist in National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), es...
Robert Whitney Newcomb Memorial Lecture and Internships
Overview Since 2001, the Robert Whitney Newcomb Memorial Fund has endowed the annual Robert Whitney Newcomb Memorial Lecture in neuroscienc...
Research Partnership in Cognitive Aging
The Problem With a rapidly growing aged population, maintaining cognitive function is critical for the health and well-being of U.S. citize...
Pre-competitive Analytical Validation of SV2A PET as a Biomarker of Synaptic Density (SV2A PET Project)
The Problem Although researchers have established biomarkers to diagnose Alzheimer’s disease, no biomarker can track cognitive decline as...
National Institute of Neurological Disorders and Stroke – Congress of Neurological Surgeons Foundation K12 Scholar Awards
Overview In 2015, the Congress of Neurological Surgeons (CNS) and the National Institute of Neurological Disorders and Stroke (NINDS) estab...
NINDS Health Disparities in Tribal Communities Summer Internship Program
Overview The NINDS Health Disparities in Tribal Communities Summer Internship Program addresses the critical need for a robust and diverse...
Biomarkers Consortium – Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)
The Problem The earliest stages of FTD are hard to detect until the disease has progressed and damage is more permanent. Experts believe th...
Biomarkers Consortium – Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease
The Problem Early treatment of Alzheimer’s disease requires early diagnosis. Yet available methods to diagnose early AD are expensive or ...
Biomarkers Consortium – Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders
The Problem Neurodegenerative and psychiatric conditions such as Alzheimer’s disease and Major Depressive Disorder present very differentl...
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
The Problem Individuals with Alzheimer’s disease often do not show symptoms during the early stages of disease, limiting clinicians’ ab...
AMP Alzheimer’s Disease 1.0
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD) was the first stage of a precompetitive partnership ...
AMP Schizophrenia 
The Accelerating Medicines Partnership® (AMP®) Program Schizophrenia (AMP SCZ) is the first neuropsychiatric project of the landmark AMP p...
AMP Parkinson’s Disease
The Accelerating Medicines Partnership® (AMP®) Program Parkinson’s disease (AMP PD) is a public-private partnership among NIH and privat...
AMP Alzheimer’s Disease 2.0
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD 2.0) is a precompetitive public-private partnership t...

Diseases

Partner With Us